In-stent thrombosis is a rare but devastating complication of coronary stent implantation, occurring in 0.5% to 1.9% of patients with bare metal stents (BMS). The most frequent clinical manifestation of stent thrombosis is ST elevation myocardial infarction (STEMI) and 30 day mortality is 50%. In-stent thrombosis can present as acute (within 24 h), subacute (within 30 days), late or very late a...

From July, 1987 to Oct, 1989 , 104 patients underwent 111 transurethral ureteroscopy procedures at the Air Force Medical Center. All intramural ureters were dilated by flexible metal dilators. The overall success rate for ureteral stone removal was 95.8 per cent. Ureteroscopy was done for evaluation of gross hematuria, strictures, ureteral stent, and ureteral and pyelocalyceal tumors. The ...

Considerable progress has been made since the initial stents were manufactured. Despite the reported side effects, cumulative evidence suggests beneficial effects in properly selected patients. The technology is still in evolution, and design modifications strive to find the perfect stent. The Dumon stent remains the gold standard against which the functions of all other stents are being measur...

Transcatheter treatments for coarctation of the aorta include balloon angioplasty and stent implantation. However, balloon angioplasty has its limitations and may be associated with complications, such as, recoarctation, dissection, and aneurysm formation, in adult patients. Bare metal stent implantation has offered an alternative during the last decade or so, but covered stents have been used ...

DRUG-ELUTING stents (DES) represent the latest percutaneous coronary intervention (PCI) designed to deal with the problem of in-stent restenosis. These stents are impregnated with a drug (sirolimus or paclitaxel) that retards the neointimal proliferation that leads to restenosis. The thrombogenic profile of DES differs from that of bare metal stents. Postprocedure dual antiplatelet therapy (clo...

BACKGROUND AND OBJECTIVES Hyaluronic acid (HA) is highly biocompatible with cells and the extracellular matrix. In contrast to degradation products of a synthetic polymer, degradation products of HA do not acidify the local environment. The aim of this study was to fabricate an HA-coated paclitaxel (PTX)-eluting stent via simple ionic interactions and to evaluate its effects in vitro and in viv...

BACKGROUND Re-endothelialization is delayed after drug-eluting stent (DES) implantation. In this setting, neointima is more prone to become lipid laden and develop neoatherosclerosis (NA), potentially increasing plaque vulnerability. METHODS AND RESULTS Optical coherence tomography and near-infrared spectroscopy with intravascular ultrasound were used to characterize NA in 65 (51 DES and 14 b...

Background—Guidelines recommend that noncardiac surgery be delayed until 30 to 45 days after bare-metal stent implantation and 1 year after drug-eluting stent implantation. Methods and Results—We used linked registry data and population-based administrative health care databases to conduct a cohort study of 8116 patients (Ն40 years of age) who underwent major elective noncardiac surgery in Onta...

Placement of metal stents is an effective therapy for patients with duodenal obstruction. Compared with palliative surgical treatment, it yields higher clinical success rates and shorter hospital stays [1,2]. Acute pancreatitis following this therapy has been reported only rarely. We report a case of acute pancreatitis following placement of a duodenal metal stent. A 59-year-old Chinese woman w...